28
Immuno 2023
Immuno 2023: Oxford Global is proud to present Immuno UK: In-Person, 28-29th March 2023, London. This unmissable event will host UK-based pharmaceutical giants, top biotech, and internationally renowned academic institutions, to share trailblazing advancements in immuno-oncology and autoimmunity.
Guided by industry leaders, Immuno UK will focus on rapidly growing therapeutic modalities, and highlight how studies into the tumour microenvironment are vastly improving our understanding of tumour biology, informing the design and delivery of future immunotherapies. We aim to showcase current translational approaches to ensure the success of these treatments and place patient safety at the forefront of immunotherapy.
Our Biomarkers stream we will be exploring how upcoming regulatory changes in the EU and UK will affect the evolving landscape of precision medicine, and what this could mean for the industries research. Senior level executives from big pharma will also be sharing emerging biomarker strategies driving therapies to the clinic.
With a dedicated full day stream exploring autoimmunity, Immuno UK will also feature talks on innovative new therapies and their journeys to the clinic. Presentations will focus on the push to evolve from immunosuppressive treatment regimens, and instead develop therapies that can restore a healthy immune system, vastly improving patient outcomes.
Key Speakers Include:
-
Patrick Fivey, Director Precision Medicine Policy, AstraZeneca
-
Sonia Iyer, Associate Director Immuno-Oncology Strategy, Translation Research, AstraZeneca
-
James Legg, Senior Vice President, Research and Early Development, Mestag Therapeutics
-
Dominik Hartl, Chief Medical Officer, Quell Therapeutics
-
Kairbaan Hodivala-Dilke, Deputy Director, Barts Cancer Institute
With over 45 presentations and panel discussions over two-days, Immuno UK will provide an ideal space to engage in high level business and scientific discussions. Join over 400 senior level delegates from the UK and benefit from global networking opportunities through our online platform. For more information about the programme and registration please contact us at d.dalby@oxfordglobal.co.uk.
|
29
Immuno 2023
Immuno 2023: Oxford Global is proud to present Immuno UK: In-Person, 28-29th March 2023, London. This unmissable event will host UK-based pharmaceutical giants, top biotech, and internationally renowned academic institutions, to share trailblazing advancements in immuno-oncology and autoimmunity.
Guided by industry leaders, Immuno UK will focus on rapidly growing therapeutic modalities, and highlight how studies into the tumour microenvironment are vastly improving our understanding of tumour biology, informing the design and delivery of future immunotherapies. We aim to showcase current translational approaches to ensure the success of these treatments and place patient safety at the forefront of immunotherapy.
Our Biomarkers stream we will be exploring how upcoming regulatory changes in the EU and UK will affect the evolving landscape of precision medicine, and what this could mean for the industries research. Senior level executives from big pharma will also be sharing emerging biomarker strategies driving therapies to the clinic.
With a dedicated full day stream exploring autoimmunity, Immuno UK will also feature talks on innovative new therapies and their journeys to the clinic. Presentations will focus on the push to evolve from immunosuppressive treatment regimens, and instead develop therapies that can restore a healthy immune system, vastly improving patient outcomes.
Key Speakers Include:
-
Patrick Fivey, Director Precision Medicine Policy, AstraZeneca
-
Sonia Iyer, Associate Director Immuno-Oncology Strategy, Translation Research, AstraZeneca
-
James Legg, Senior Vice President, Research and Early Development, Mestag Therapeutics
-
Dominik Hartl, Chief Medical Officer, Quell Therapeutics
-
Kairbaan Hodivala-Dilke, Deputy Director, Barts Cancer Institute
With over 45 presentations and panel discussions over two-days, Immuno UK will provide an ideal space to engage in high level business and scientific discussions. Join over 400 senior level delegates from the UK and benefit from global networking opportunities through our online platform. For more information about the programme and registration please contact us at d.dalby@oxfordglobal.co.uk.
|
30
NextGen Omics US 2023
NextGen Omics US 2023: Join our 8th Annual NextGen Omics US Series taking place on the 30-31 March 2023, Boston, MA. Featuring advancements in Genome Sequencing & Clinical Diagnostics Development, Multi-omics Spatial Analysis & Single Cell Analysis. Attracting over 300 attendees from leading healthcare and academic institutions as well as leading pharmaceutical and biotech companies, this event will feature innovative insights into the following areas:
Benefit from:
-
Advancing clinical genomics and diagnostics research and analysis as well as bioinformatics tools. Presentations will include advances in covid-19 research, delivering clinical diagnostics and applying genome sequencing to disease prevention –
-
Key speakers include James Willey, Professor, The University of Toledo, Gang Wu, Director, St. Jude Children's Research Hospital, and Carlo Bifulco, MD, Providence Portland Medical Center
-
Discussing the latest innovations in spatial omics technologies. Hear in-depth presentations from spatial genomics, transcriptomics, metabolomics and proteomics to driving diagnostics and therapeutic development.
-
Key speakers include Yong Kee Choi, Senior Scientist, Alnylam Pharmaceuticals, Steven Wang, Assistant Professor of Genetics & Cell Biology, Yale University, and Guo-Cheng Yuan, Professor of Computational Biology, Icahn School of Medicine at Mount Sinai
-
Application of single cell tools, data analysis and translation in the clinic : from current & emerging technology and analysis tools development to single cell analysis in drug development and in the clinic
-
Key speakers include Ditte Lovatt, Associate Principal Scientist, Merck, Sangita Choudhury, Assistant Professor, Department of Pediatrics, Harvard Medical School Boston Children's Hospital, and Devan Phillips, Senior Scientific Researcher, Genentech
For the latest conference updates follow us on Twitter @NGSUSCongress and join the discussion on or contact us directly at marketing@oxfordglobal.co.uk.
Biologics 2023
Biologics 2023: Oxford Global’s 16th Annual Proteins & Antibodies Congress, 30 – 31 March 2023, London, UK will be attended by over 400 visionary leaders to network about the latest innovations in the field.
With a revamped agenda, visionary leaders will be looking at novel computational approaches & tools, AI/ML utilisation as well as advanced engineering methods, bioanalysis and cell engagers.
Featuring a pre-event focus day on 29th March with the opening event keynote address on ‘Antibody Discovery & Engineering In A Chronic Disease Management Perspective; delivered by Erik Vernet, Director of Antibody Technology, Novo Nordisk.
The event will be looking at the following main themes:
- Day 1 Track 1: Antibody-Based Molecular Engineering
- Day 1 Track 2: Emerging Techniques for Bioanalysis & Characterisation and Quality Control Systems
- Day 2 Track 1 – Computational Tools, Structural Approaches & Automation in Engineering
- Day 2 Track 2 – Multi Specific Antibodies, Cell Engagers & Other New Modalities
Key Speakers Include:
- Aneesh Karatt Vellatt, Chief Scientific Officer, Maxion Therapeutics
- Annelise Vuidepot, Chief Technology Officer, Immunocore
- Dan Snell, Vice President, Translational Sciences, Numab Therapeutics
- Stefan Warmuth, Vice President, Protein Engineering & CMC, Numab Therapeutics
- Colette Johnston, Vice President, Discovery, Crescendo Biologics
- Amita Datta-Mannan, Associate Vice President, Eli Lilly & Company
- Samuel Pine, Senior Director and Head of Bioanalysis and Immunogenicity, Sanofi
- Maria Knudsen, Director, Salipro Biotech
- Ryan Fiehler, Associate Director, Discovery, F-star Therapeutics
- Stefan Grüner, Associate Director of Protein Engineering, Pieris Pharmaceuticals
Featuring a series of dedicated interactive sessions:
- Panel Discussion: Different Technologies In Antibody Engineering
- Panel Discussion: Immunogenicity Of New Modalities
- Roundtable: Influence Of Biologics Physio-Chemical Properties On PK & Disposition
- Roundtable: Bioassay Strategies For Biologics Identification
- Workshop: Integration Of Data For AI/ML & Structural Modelling
- Workshop: T Cell Engager Biology And Therapeutic Strategies
Co-located with the Peptides & Oligonucleotides Congress. For more information contact marketing@oxfordglobal.co.uk.
|
31
NextGen Omics US 2023
NextGen Omics US 2023: Join our 8th Annual NextGen Omics US Series taking place on the 30-31 March 2023, Boston, MA. Featuring advancements in Genome Sequencing & Clinical Diagnostics Development, Multi-omics Spatial Analysis & Single Cell Analysis. Attracting over 300 attendees from leading healthcare and academic institutions as well as leading pharmaceutical and biotech companies, this event will feature innovative insights into the following areas:
Benefit from:
-
Advancing clinical genomics and diagnostics research and analysis as well as bioinformatics tools. Presentations will include advances in covid-19 research, delivering clinical diagnostics and applying genome sequencing to disease prevention –
-
Key speakers include James Willey, Professor, The University of Toledo, Gang Wu, Director, St. Jude Children's Research Hospital, and Carlo Bifulco, MD, Providence Portland Medical Center
-
Discussing the latest innovations in spatial omics technologies. Hear in-depth presentations from spatial genomics, transcriptomics, metabolomics and proteomics to driving diagnostics and therapeutic development.
-
Key speakers include Yong Kee Choi, Senior Scientist, Alnylam Pharmaceuticals, Steven Wang, Assistant Professor of Genetics & Cell Biology, Yale University, and Guo-Cheng Yuan, Professor of Computational Biology, Icahn School of Medicine at Mount Sinai
-
Application of single cell tools, data analysis and translation in the clinic : from current & emerging technology and analysis tools development to single cell analysis in drug development and in the clinic
-
Key speakers include Ditte Lovatt, Associate Principal Scientist, Merck, Sangita Choudhury, Assistant Professor, Department of Pediatrics, Harvard Medical School Boston Children's Hospital, and Devan Phillips, Senior Scientific Researcher, Genentech
For the latest conference updates follow us on Twitter @NGSUSCongress and join the discussion on or contact us directly at marketing@oxfordglobal.co.uk.
Biologics 2023
Biologics 2023: Oxford Global’s 16th Annual Proteins & Antibodies Congress, 30 – 31 March 2023, London, UK will be attended by over 400 visionary leaders to network about the latest innovations in the field.
With a revamped agenda, visionary leaders will be looking at novel computational approaches & tools, AI/ML utilisation as well as advanced engineering methods, bioanalysis and cell engagers.
Featuring a pre-event focus day on 29th March with the opening event keynote address on ‘Antibody Discovery & Engineering In A Chronic Disease Management Perspective; delivered by Erik Vernet, Director of Antibody Technology, Novo Nordisk.
The event will be looking at the following main themes:
- Day 1 Track 1: Antibody-Based Molecular Engineering
- Day 1 Track 2: Emerging Techniques for Bioanalysis & Characterisation and Quality Control Systems
- Day 2 Track 1 – Computational Tools, Structural Approaches & Automation in Engineering
- Day 2 Track 2 – Multi Specific Antibodies, Cell Engagers & Other New Modalities
Key Speakers Include:
- Aneesh Karatt Vellatt, Chief Scientific Officer, Maxion Therapeutics
- Annelise Vuidepot, Chief Technology Officer, Immunocore
- Dan Snell, Vice President, Translational Sciences, Numab Therapeutics
- Stefan Warmuth, Vice President, Protein Engineering & CMC, Numab Therapeutics
- Colette Johnston, Vice President, Discovery, Crescendo Biologics
- Amita Datta-Mannan, Associate Vice President, Eli Lilly & Company
- Samuel Pine, Senior Director and Head of Bioanalysis and Immunogenicity, Sanofi
- Maria Knudsen, Director, Salipro Biotech
- Ryan Fiehler, Associate Director, Discovery, F-star Therapeutics
- Stefan Grüner, Associate Director of Protein Engineering, Pieris Pharmaceuticals
Featuring a series of dedicated interactive sessions:
- Panel Discussion: Different Technologies In Antibody Engineering
- Panel Discussion: Immunogenicity Of New Modalities
- Roundtable: Influence Of Biologics Physio-Chemical Properties On PK & Disposition
- Roundtable: Bioassay Strategies For Biologics Identification
- Workshop: Integration Of Data For AI/ML & Structural Modelling
- Workshop: T Cell Engager Biology And Therapeutic Strategies
Co-located with the Peptides & Oligonucleotides Congress. For more information contact marketing@oxfordglobal.co.uk.
|
|
|
|